Henk M W Verheul

List of Publications by Year
in descending order

295	11,263	36303	36028
papers	citations	51 h-index	97 g-index

301	301	301	17220
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncology, The, 2015, 16, 1090-1098.	10.7	1,861
2	Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews Cancer, 2007, 7, 475-485.	28.4	468
3	Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. Angiogenesis, 2010, 13, 1-14.	7.2	408
4	Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 616-628.	10.7	397
5	Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1Î±. Cancer Research, 2006, 66, 8814-8821.	0.9	292
6	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. Journal of Clinical Oncology, 2021, 39, 1995-2004.	1.6	291
7	Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2016, 34, 1339-1344.	1.6	279
8	Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance. Clinical Cancer Research, 2011, 17, 7337-7346.	7.0	275
9	Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resistance Updates, 2009, 12, 114-126.	14.4	196
10	The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer. Clinical Cancer Research, 2010, 16, 1613-1623.	7.0	193
11	Vascular endothelial growth factorâ€“stimulated endothelial cells promote adhesion and activation of platelets. Blood, 2000, 96, 4216-4221.	1.4	187
12	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nature Communications, 2020, 11, 525.	12.8	158
13	The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Frontiers in Immunology, 2017, 8, 631.	4.8	154
14	Colorectal liver metastases: surgery versus thermal ablation (COLLISION) â€“ a phase III single-blind prospective randomized controlled trial. BMC Cancer, 2018, 18, 821.	2.6	154
15	Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. Journal of Neuro-Oncology, 2017, 135, 183-192.	2.9	138
16	Signalling pathways in vasculogenic mimicry. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 18-28.	7.4	135
17	Lymph Node Retrieval During Esophagectomy With and Without Neoadjuvant Chemoradiotherapy. Annals of Surgery, 2014, 260, 786-793.	4.2	134
18	Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model. Clinical Cancer Research, 2007, 13, 4201-4208.	7.0	111

#	Article	IF	Citations
19	Proteomics of the TRAP-induced platelet releasate. Journal of Proteomics, 2009, 72, 91-109.	2.4	108
20	89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget, 2015, 6, 30384-30393.	1.8	106
21	Platelets Take Up the Monoclonal Antibody Bevacizumab. Clinical Cancer Research, 2007, 13, 5341-5347.	7.0	105
22	Combination Strategy Targeting the Hypoxia Inducible Factor-1Î± with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors. Clinical Cancer Research, 2008, 14, 3589-3597.	7.0	105
23	Effects of Chemotherapy on Pathologic and Biologic Characteristics of Locally Advanced Breast Cancer. American Journal of Clinical Pathology, 1997, 107, 211-218.	0.7	104
24	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. Journal of Clinical Oncology, 2018, 36, 268-275.	1.6	91
25	First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget, 2016, 7, 80046-80058.	1.8	90
26	Clinical experience with Î±-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clinical Immunology, 2011, 140, 130-141.	3.2	87
27	Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer, 2019, 19, 390.	2.6	83
28	Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 4538-4546.	7.0	82
29	Vascular Endothelial Growth Factor-165 Overexpression Stimulates Angiogenesis and Induces Cyst Formation and Macrophage Infiltration in Human Ovarian Cancer Xenografts. American Journal of Pathology, 2002, 160, 537-548.	3.8	80
30	Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications. Clinical Biochemistry, 2013, 46, 466-479.	1.9	80
31	Bispecific antibody platforms for cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2014, 92, 153-165.	4.4	78
32	The Role of Vascular Endothelial Growth Factor (VEGF) in Tumor Angiogenesis and Early Clinical Development of VEGFReceptor Kinase Inhibitors. Clinical Breast Cancer, 2000, 1, S80-S84.	2.4	77
33	ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibodyâ€“Drug Conjugate Treatment. Clinical Cancer Research, 2016, 22, 1642-1652.	7.0	74
34	Muscle mass as a target to reduce fatigue in patients with advanced cancer. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 623-629.	7.3	72
35	Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. PLoS ONE, 2016, 11, e0157830.	2.5	69
36	Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. Scientific Reports, 2017, 7, 44686.	3.3	66

#	Article	IF	Citations
37	Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review. Annals of Oncology, 2014, 25, 1914-1918.	1.2	65
38	A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. British Journal of Cancer, 2021, 124, 728-735.	6.4	64
39	Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis, 2011, 14, 135-141.	7.2	62
40	The influence of different muscle mass measurements on the diagnosis of cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 615-622.	7.3	62
41	Subnuclear Proteomics in Colorectal Cancer. Molecular and Cellular Proteomics, 2010, 9, 988-1005.	3.8	61
42	Genomic landscape of metastatic colorectal cancer. Nature Communications, 2014, 5, 5457.	12.8	61
43	Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. Cancers, 2016, 8, 81.	3.7	61
44	A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vî³9Vî2-T cells. OncoImmunology, 2018, 7, e1375641.	4.6	61
45	Higher Muscle Strength Is Associated with Prolonged Survival in Older Patients with Advanced Cancer. Oncologist, 2018, 23, 580-585.	3.7	61
46	Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clinical Cancer Research, 2002, 8, 3747-54.	7.0	61
47	Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. Experimental and Molecular Medicine, 2018, 50, e454-e454.	7.7	59
48	Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis, 2009, 12, 69-79.	7.2	58
49	Aiming for a Better Understanding and Management of Cancer-Related Fatigue. Oncologist, 2013, 18, 1135-1143.	3.7	58
50	Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. BMC Cancer, 2015, 15, 180.	2.6	57
51	Predictive biomarkers in renal cell cancer: Insights in drug resistance mechanisms. Drug Resistance Updates, 2014, 17, 77-88.	14.4	56
52	Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1931-1939.	6.4	53
53	<scp>INKA</scp> , an integrative data analysis pipeline for phosphoproteomic inference of active kinases. Molecular Systems Biology, 2019, 15, e8250.	7.2	53
54	Circulating Invariant Natural Killer T-Cell Numbers Predict Outcome in Head and Neck Squamous Cell Carcinoma: Updated Analysis With 10-Year Follow-Up. Journal of Clinical Oncology, 2012, 30, 567-570.	1.6	52

#	Article	IF	Citations
55	Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. European Urology, 2016, 70, 416-426.	1.9	51
56	Immuno-PET Imaging to Assess Target Engagement: Experience from ⁸⁹Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. Journal of Nuclear Medicine, 2019, 60, 902-909.	5.0	50
57	Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. Journal of Nuclear Medicine, 2017, 58, 1906-1912.	5.0	48
58	The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review. Cancers, 2020, 12, 586.	3.7	48
59	Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cellular Oncology (Dordrecht), 2015, 38, 119-129.	4.4	46
60	Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines. Journal of Proteomics, 2015, 127, 247-258.	2.4	45
61	Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics. Journal of Proteomics, 2015, 127, 259-263.	2.4	43
62	In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. Frontiers in Immunology, 2017, 8, 87.	4.8	43
63	CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clinical Cancer Research, 2015, 21, 2753-2762.	7.0	42
64	Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. Clinical Therapeutics, 2016, 38, 2286-2299.	2.5	42
65	Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. Nature Medicine, 2021, 27, 1553-1563.	30.7	41
66	Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. Advances in Therapy, 2015, 32, 510-522.	2.9	39
67	Surgery of the primary in stage IV colorectal cancer with unresectable metastases. European Journal of Cancer, 2011, 47, S61-S66.	2.8	37
68	Mass Spectrometry-Based Proteomics: From Cancer Biology to Protein Biomarkers, Drug Targets, and Clinical Applications. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e504-e510.	3.8	37
69	ShrinkBayes: a versatile R-package for analysis of count-based sequencing data in complex study designs. BMC Bioinformatics, 2014, 15, 116.	2.6	37
70	Targeting JNK-interacting protein 1 (JIP1) sensitises osteosarcoma to doxorubicin. Oncotarget, 2012, 3, 1169-1181.	1.8	36
71	The Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.0	35
72	New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?. Clinical Genitourinary Cancer, 2015, 13, 271-279.	1.9	34

#	Article	IF	Citations
73	Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases. JAMA Surgery, 2021, 156, 710-720.	4.3	34
74	Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment. JAMA Surgery, 2021, 156, 1093.	4.3	34
75	Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT. Clinical Genitourinary Cancer, 2017, 15, e773-e782.	1.9	33
76	Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Epigenetics, 2013, 8, 907-920.	2.7	32
77	Sunitinib activates Axl signaling in renal cell cancer. International Journal of Cancer, 2016, 138, 3002-3010.	5.1	32
78	<scp>RAS</scp> and <scp>BRAF</scp> mutations in cellâ€free <scp>DNA</scp> are predictive for outcome of cetuximab monotherapy in patients with tissueâ€tested <scp>RAS</scp> wildâ€type advanced colorectal cancer. Molecular Oncology, 2019, 13, 2361-2374.	4.6	32
79	Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection. Journal of Proteomics, 2017, 162, 99-107.	2.4	31
80	Feasibility, validity and reliability of objective smartphone measurements of physical activity and fitness in patients with cancer. BMC Cancer, 2018, 18, 1052.	2.6	31
81	Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. Analytical and Bioanalytical Chemistry, 2010, 397, 3163-3171.	3.7	29
82	Weight Loss of 5% or More Predicts Loss of Fat-Free Mass During Palliative Chemotherapy in Patients With Advanced Cancer: A Pilot Study. Nutrition and Cancer, 2012, 64, 826-832.	2.0	29
83	Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer. Journal of Extracellular Vesicles, 2014, 3, 25657.	12.2	29
84	Highly specific and potently activating VÎ³9VÎ´2-T cell specific nanobodies for diagnostic and therapeutic applications. Clinical Immunology, 2016, 169, 128-138.	3.2	29
85	Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines. Molecular and Cellular Proteomics, 2020, 19, 884-899.	3.8	29
86	Losses of Chromosome 5q and 14q Are Associated with Favorable Clinical Outcome of Patients with Gastric Cancer. Oncologist, 2012, 17, 653-662.	3.7	27
87	Dried blood spot analysis for therapeutic drug monitoring of pazopanib. Journal of Clinical Pharmacology, 2015, 55, 1344-1350.	2.0	26
88	The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis, 2017, 20, 217-232.	7.2	26
89	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. Journal of Clinical Oncology, 2018, 36, 2052-2060.	1.6	26
90	Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience, 2014, 1, 844-853.	2.2	26

#	Article	IF	Citations
91	Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. Cancer and Metastasis Reviews, 2017, 36, 395-406.	5.9	25
92	Proteomic Analysis of miR-195 and miR-497 Replacement Reveals Potential Candidates that Increase Sensitivity to Oxaliplatin in MSI/P53wt Colorectal Cancer Cells. Cells, 2019, 8, 1111.	4.1	25
93	Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment. Clinical Cancer Research, 2022, 28, 1402-1411.	7.0	24
94	Circulating endothelial cells in cancer patients do not express tissue factor. Cancer Letters, 2004, 213, 241-248.	7.2	23
95	Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care. Cellular Oncology (Dordrecht), 2015, 38, 49-64.	4.4	23
96	Vaccination approach to anti-angiogenic treatment of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 155-171.	7.4	22
97	Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer. Experimental and Molecular Medicine, 2016, 48, e279-e279.	7.7	22
98	Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemotherapy and Pharmacology, 2007, 60, 329-339.	2.3	21
99	Analysis of the Novel Fanconi Anemia GeneSLX4/FANCPin Familial Breast Cancer Cases. Human Mutation, 2013, 34, 70-73.	2.5	21
100	Mass Spectrometry-Based Serum and Plasma Peptidome Profiling for Prediction of Treatment Outcome in Patients With Solid Malignancies. Oncologist, 2014, 19, 1028-1039.	3.7	21
101	Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2404-2412.	6.4	21
102	Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Annals of Oncology, 2019, 30, 663-665.	1.2	21
103	Insight in taste alterations during treatment with protein kinase inhibitors. European Journal of Cancer, 2017, 86, 125-134.	2.8	20
104	A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. European Journal of Cancer, 2018, 90, 1-9.	2.8	20
105	Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab. Angiogenesis, 2018, 21, 325-334.	7.2	20
106	Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. PLoS ONE, 2018, 13, e0201809.	2.5	20
107	Accuracy of the Delirium Observational Screening Scale (DOS) as a screening tool for delirium in patients with advanced cancer. BMC Cancer, 2019, 19, 160.	2.6	20
108	Treatment of the Kasabach-Merritt Syndrome with Pegylated Recombinant Human Megakaryocyte Growth and Development Factor in Mice: Elevated Platelet Counts, Prolonged Survival, and Tumor Growth Inhibition. Pediatric Research, 1999, 46, 562-562.	2.3	20

#	Article	IF	Citations
109	Inhibition of angiogenesis in cancer patients. Expert Opinion on Emerging Drugs, 2005, 10, 403-412.	2.4	19
110	Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma. Oncology Letters, 2012, 3, 1293-1296.	1.8	19
111	CD1d-Restricted Antigen Presentation by Vî³9Vî´2-T Cells Requires Trogocytosis. Cancer Immunology Research, 2014, 2, 732-740.	3.4	19
112	Platelets: an unexploited data source in biomarker research. Lancet Haematology,the, 2015, 2, e512-e513.	4.6	19
113	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1875.	3.7	19
114	Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era. British Journal of Cancer, 2021, 124, 399-406.	6.4	19
115	Abstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma. Cancer Research, 2014, 74, CT216-CT216.	0.9	19
116	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget, 2017, 8, 63140-63154.	1.8	19
117	Screening and treatment of psychological distress in patients with metastatic colorectal cancer: study protocol of the TES trial. BMC Cancer, 2015, 15, 302.	2.6	18
118	Bevacizumab in Combination With Radiotherapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme. Oncologist, 2015, 20, 107-108.	3.7	18
119	Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC. Annals of Surgical Oncology, 2018, 25, 2347-2356.	1.5	18
120	Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. BMC Cancer, 2019, 19, 1066.	2.6	18
121	Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. Cancers, 2021, 13, 711.	3.7	18
122	The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer. Journal of Kidney Cancer and VHL, 2015, 2, 195-203.	1.0	18
123	Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth. Journal of Experimental and Clinical Cancer Research, 2016, 35, 138.	8.6	17
124	Activated iNKT cells promote Vî³9Vî´2-T cell anti-tumor effector functions through the production of TNF-Î±. Clinical Immunology, 2012, 142, 194-200.	3.2	16
125	Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2019, 37, 411-418.	1.6	16
126	Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 161.	8.6	16

#	Article	IF	Citations
127	Screening and Stepped Care Targeting Psychological Distress in Patients With Metastatic Colorectal Cancer: The TES Cluster Randomized Trial. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 911-920.	4.9	16
128	A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1319-1327.	6.4	15
129	Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treatment Reviews, 2022, 109, 102433.	7.7	15
130	The effect of individualized NUTritional counseling on muscle mass and treatment outcome in patients with metastatic COLOrectal cancer undergoing chemotherapy: a randomized controlled trial protocol. BMC Cancer, 2015, 15, 98.	2.6	14
131	Plasma Ghrelin Levels Are Associated with Anorexia but Not Cachexia in Patients with NSCLC. Frontiers in Physiology, 2017, 8, 119.	2.8	14
132	Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform. Lancet Oncology, The, 2022, 23, 198-201.	10.7	14
133	Successful Treatment of Renal Cell Carcinoma With Sorafenib After Effective but Hepatotoxic Sunitinib Exposure. Journal of Clinical Oncology, 2013, 31, e83-e86.	1.6	13
134	Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. BMC Palliative Care, 2014, 13, 42.	1.8	13
135	Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma. Journal of Neuro-Oncology, 2016, 129, 221-230.	2.9	13
136	Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-NaÃ¯ve Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1481-1488.	4.9	13
137	Cancer Cachexia: Identification by Clinical Assessment versus International Consensus Criteria in Patients with Metastatic Colorectal Cancer. Nutrition and Cancer, 2018, 70, 1322-1329.	2.0	13
138	Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study. Physiological Reports, 2021, 9, e14919.	1.7	13
139	Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study. EJNMMI Research, 2020, 10, 40.	2.5	13
140	High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. Cellular Oncology (Dordrecht), 2014, 37, 41-52.	4.4	12
141	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 4569-4575.	7.0	12
142	Identification of patients with cancer with a high risk to develop delirium. Cancer Medicine, 2017, 6, 1861-1870.	2.8	12
143	Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection. BMC Bioinformatics, 2018, 19, 301.	2.6	12
144	Predictors for use of psychosocial services in patients with metastatic colorectal cancer receiving first line systemic treatment. BMC Cancer, 2019, 19, 115.	2.6	12

#	Article	IF	Citations
145	CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.. Journal of Clinical Oncology, 2015, 33, 3016-3016.	1.6	12
146	Clinical assessment of emotions in patients with cancer: Diagnostic accuracy compared to two reference standards.. Journal of Clinical Oncology, 2017, 35, 24-24.	1.6	12
147	Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor. Cancers, 2021, 13, 5446.	3.7	12
148	Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2022, 28, 1595-1602.	7.0	12
149	A Multiple-Loop, Double-Cube Microarray Design Applied to Prostate Cancer Cell Lines with Variable Sensitivity to Histone Deacetylase Inhibitors. Clinical Cancer Research, 2008, 14, 6886-6894.	7.0	11
150	Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2010, 16, 2187-2197.	7.0	11
151	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. OncoImmunology, 2016, 5, e1105431.	4.6	11
152	Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e1-e9.	1.9	11
153	Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody. EJNMMI Research, 2018, 8, 6.	2.5	11
154	Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome. Cancers, 2020, 12, 330.	3.7	11
155	Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity. International Journal for Quality in Health Care, 2021, 33, .	1.8	11
156	Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) â€" Results of the Dutch HOVON 123 Study. Blood, 2018, 132, 1889-1889.	1.4	11
157	Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. Digestion, 2016, 94, 129-137.	2.3	10
158	The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy. Cancer Management and Research, 2018, Volume 10, 3015-3021.	1.9	10
159	Optimal treatment of opioid induced constipation in daily clinical practice â€" an observational study. BMC Palliative Care, 2019, 18, 31.	1.8	10
160	How Does a Supervised Exercise Program Improve Quality of Life in Patients with Cancer? A Concept Mapping Study Examining Patients' Perspectives. Oncologist, 2019, 24, e374-e383.	3.7	10
161	Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. Oncologist, 2020, 25, e570-e577.	3.7	10
162	Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. Cancers, 2020, 12, 3322.	3.7	10

#	Article	IF	Citations
163	Diagnostic Performance of [18F]FDG PET in Staging Grade 1â€“2, Estrogen Receptor Positive Breast Cancer. Diagnostics, 2021, 11, 1954.	2.6	10
164	Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials. Supportive Care in Cancer, 2015, 23, 2499-2506.	2.2	9
165	Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity. Angiogenesis, 2017, 20, 287-289.	7.2	9
166	Prevention of Vî³9Vî´2 T Cell Activation by a Vî³9Vî´2 TCR Nanobody. Journal of Immunology, 2017, 198, 308-317.	0.8	9
167	Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone. Clinical Genitourinary Cancer, 2019, 17, e281-e292.	1.9	9
168	A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer. Cancer Medicine, 2020, 9, 7558-7571.	2.8	9
169	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. Clinical Cancer Research, 2021, 27, 6106-6114.	7.0	9
170	A Novel Splice Site Mutation in the Noncoding Region ofBRCA2: Implications for Fanconi Anemia and Familial Breast Cancer Diagnostics. Human Mutation, 2014, 35, 442-446.	2.5	8
171	What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study. Cancer Epidemiology, 2015, 39, 848-853.	1.9	8
172	The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer. European Journal of Cancer, 2018, 103, 160-164.	2.8	8
173	Constitutively active GSK3Î² as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression. OncoImmunology, 2019, 8, e1631119.	4.6	8
174	Muscle contractile properties of cancer patients receiving chemotherapy: Assessment of feasibility and exercise effects. Scandinavian Journal of Medicine and Science in Sports, 2020, 30, 1918-1929.	2.9	8
175	High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review. Cancer Treatment Reviews, 2021, 97, 102171.	7.7	8
176	Effects of Cancer Presence and Therapy on the Platelet Proteome. International Journal of Molecular Sciences, 2021, 22, 8236.	4.1	8
177	Clinical management of emotions in patients with cancer: introducing the approach â€œemotional support and case findingâ€• Translational Behavioral Medicine, 2020, 10, 1399-1405.	2.4	8
178	Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer. Oncologist, 2020, 25, e1195-e1201.	3.7	7
179	Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial. Oncologist, 2021, 26, e173-e181.	3.7	7
180	Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies. Molecular Oncology, 2021, 15, 901-914.	4.6	7

#	Article	IF	Citations
181	The future of colorectal cancer: implications of screening. Gut, 2013, 62, 1387-1389.	12.1	6
182	A safety and immunogenicity study of immunization with hVEGF 26-104 /RFASE in cynomolgus monkeys. Vaccine, 2018, 36, 2025-2032.	3.8	6
183	Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus Surgery Without HIPEC for Goblet-Cell Carcinoids and Mixed Adenoneuroendocrine Carcinomas: Propensity Scoreâ€"Matched Analysis of Centers in the Netherlands and Belgium. Clinical Colorectal Cancer, 2020, 19, e87-e99.	2.3	6
184	A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors.. Journal of Clinical Oncology, 2017, 35, 2556-2556.	1.6	6
185	Development of a miRNAâ€based classifier for detection of colorectal cancer molecular subtypes. Molecular Oncology, 2022, 16, 2693-2709.	4.6	6
186	Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. Medical Oncology, 2011, 28, 1136-1139.	2.5	5
187	Novel strategies towards the use of anti-angiogenic agents in breast cancer. European Journal of Pharmacology, 2013, 717, 36-39.	3.5	5
188	Optimal Human Blood Sampling for Platelet Research. Current Angiogenesis, 2014, 2, 157-161.	0.1	5
189	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Scientific Reports, 2020, 10, 9778.	3.3	5
190	CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer. Cells, 2020, 9, 124.	4.1	5
191	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clinical and Translational Science, 2021, 14, 954-963.	3.1	5
192	A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).. Journal of Clinical Oncology, 2014, 32, 2529-2529.	1.6	5
193	Identification of novel therapeutic targets in glioblastoma with functional genomic mRNA profiling.. Journal of Clinical Oncology, 2017, 35, 2018-2018.	1.6	5
194	Response and toxicity prediction by MALDIâ€TOFâ€MS serum peptide profiling in patients with nonâ€small cell lung cancer. Proteomics - Clinical Applications, 2016, 10, 743-749.	1.6	4
195	A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. British Journal of Cancer, 2016, 115, 940-948.	6.4	4
196	The effects of systemic treatment with aminobisphosphonates and statins on circulating Vî³9Vî´2-T cells in patients with advanced cancer. Immunobiology, 2018, 223, 171-177.	1.9	4
197	Clinical assessment of emotions in patients with cancer: Diagnostic accuracy compared with two reference standards. Psycho-Oncology, 2020, 29, 775-780.	2.3	4
198	A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26â€"104/RFASE in Patients with Advanced Solid Malignancies. Oncologist, 2021, 26, e218-e229.	3.7	4

#	Article	IF	Citations
199	The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy. Cancer Treatment and Research Communications, 2021, 27, 100371.	1.7	4
200	Abstract OT3-2-01: IMPACT: IMaging PAtients for Cancer drug selecTion â€“ Metastatic breast cancer (MBC). , 2015, , .		4
201	Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. PLoS ONE, 2016, 11, e0155178.	2.5	4
202	Reply to L.E. Daly et al. Journal of Clinical Oncology, 2016, 34, 3817-3817.	1.6	3
203	Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study. Cancer Chemotherapy and Pharmacology, 2020, 86, 141-150.	2.3	3
204	Predicting outcome in older patients with cancer: Comprehensive geriatric assessment and clinical judgment. Journal of Geriatric Oncology, 2021, 12, 49-56.	1.0	3
205	Abstract 2989: High-dose, intermittent sunitinib as an alternative treatment strategy. , 2014, , .		3
206	Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, TPS3097-TPS3097.	1.6	3
207	Screening and stepped care targeting psychological distress in patients with metastatic colorectal cancer: The TES cluster randomized trial.. Journal of Clinical Oncology, 2018, 36, 3560-3560.	1.6	3
208	First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using ⁸⁹Zr-Df-CPC634 PET/CT.. Journal of Clinical Oncology, 2019, 37, 3093-3093.	1.6	3
209	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells. Clinical Immunology, 2015, 158, 92-99.	3.2	2
210	A Phase 1 Trial of Cabazitaxel Combined With 188Reâ€“Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment. Clinical Nuclear Medicine, 2017, 42, 415-420.	1.3	2
211	Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study. Oncologist, 2018, 23, 1135.	3.7	2
212	Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials. Supportive Care in Cancer, 2021, 29, 3783-3792.	2.2	2
213	Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients. Clinical Proteomics, 2021, 18, 8.	2.1	2
214	Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology. Cancers, 2021, 13, 2304.	3.7	2
215	Abstract 2496: Preclinical testing of a novel anti-angiogenic vaccine targeting human VEGF. , 2015, , .		2
216	Abstract CT017: A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients. , 2016, , .		2

#	Article	IF	Citations
217	Tumor, skin, and plasma concentrations of protein kinase inhibitors (PKIs) in patients with advanced cancer.. Journal of Clinical Oncology, 2013, 31, 11087-11087.	1.6	2
218	ImmunoPET imaging with 89Zr-cetuximab in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 11102-11102.	1.6	2
219	Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, 11553-11553.	1.6	2
220	Pharmacokinetic (PK) effects and safety of olaparib in combination with tamoxifen, anastrozole, or letrozole: Phase I study.. Journal of Clinical Oncology, 2016, 34, 2562-2562.	1.6	2
221	The ORCHESTRA trial: A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, TPS788-TPS788.	1.6	2
222	Pharmacokinetics of cetuximab and tumor uptake of ⁸⁹Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15117-e15117.	1.6	2
223	A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.. Journal of Clinical Oncology, 2017, 35, 166-166.	1.6	2
224	Circulating tumor DNA dynamics in resectable gastric cancer.. Journal of Clinical Oncology, 2018, 36, 4069-4069.	1.6	2
225	CD276-positive circulating endothelial cells in advanced colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 572-572.	1.6	2
226	Research Highlights. Immunotherapy, 2012, 4, 19-21.	2.0	1
227	Vî³9Vî´2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy. OncoImmunology, 2014, 3, e955343.	4.6	1
228	FDG PET and FES PET Predict PFS on Endocrine Therapyâ€"Letter. Clinical Cancer Research, 2018, 24, 248-248.	7.0	1
229	Taste Alterations During Treatment With Protein Kinase Inhibitors: A Pilot Study. Journal of Pain and Symptom Management, 2018, 56, e1-e4.	1.2	1
230	10-year outcome of a randomized trial comparing neoadjuvant chemoradiotherapy and surgery with surgery alone for esophageal cancer (CROSS trial). European Journal of Surgical Oncology, 2021, 47, e31.	1.0	1
231	Angiogenesis inhibitors: What is the clinical future?. , 2005, 63, 67-91.		1
232	Abstract 176: Kinase activity of tumor-derived exosomes as a potential biomarker for response to treatment. , 2012, , .		1
233	Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation.. Journal of Clinical Oncology, 2014, 32, 2599-2599.	1.6	1
234	Identification of patients at risk for delirium on a medical oncology hospital ward.. Journal of Clinical Oncology, 2014, 32, 130-130.	1.6	1

#	Article	IF	Citations
235	Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies.. Journal of Clinical Oncology, 2015, 33, 2565-2565.	1.6	1
236	A novel combinatorial therapy using cytolytic NK cells and anti-EGFR moAb to improve the treatment of EGFR expressing solid tumors.. Journal of Clinical Oncology, 2015, 33, e14017-e14017.	1.6	1
237	A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.. Journal of Clinical Oncology, 2016, 34, 5081-5081.	1.6	1
238	A phase I trial of cabazitaxel Â± rhenium-188-HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment.. Journal of Clinical Oncology, 2016, 34, e16508-e16508.	1.6	1
239	A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 2591-2591.	1.6	1
240	The impact of cumulative toxicity on physical quality of life in patients with metastatic colorectal cancer receiving first line chemotherapy.. Journal of Clinical Oncology, 2017, 35, 3564-3564.	1.6	1
241	Genome-wide methylation profiling to identify potential epigenetic biomarkers associated with response to sunitinib in metastatic renal cell cancer (mRCC) patients (pts).. Journal of Clinical Oncology, 2013, 31, 4566-4566.	1.6	1
242	A phase I study of investigational agent SGI-110 combined with irinotecan in previously treated metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2015, 33, TPS797-TPS797.	1.6	1
243	Efficacy and side effect profile of olanzapine versus haloperidol for symptoms of delirium in hospitalized patients with advanced cancer: A multicenter, investigator-blinded, randomized, controlled trial (RCT).. Journal of Clinical Oncology, 2017, 35, 231-231.	1.6	1
244	A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso.. Journal of Clinical Oncology, 2018, 36, e15584-e15584.	1.6	1
245	Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa151.	0.7	1
246	Clinical judgment of the need for professional mental health care in patients with cancer: a qualitative study among oncologists and nurses. Journal of Cancer Survivorship, 2021, , 1.	2.9	1
247	In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival. Annals of Surgical Oncology, 2022, 29, 5256-5262.	1.5	1
248	Case 19-2009: Carcinoma of the Gastroesophageal Junction. New England Journal of Medicine, 2009, 361, 1315-1316.	27.0	0
249	Patient-Reported Symptom Monitoring During Chemotherapy. JAMA - Journal of the American Medical Association, 2017, 318, 1935.	7.4	0
250	O200 10-YEAR FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL COMPARING NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VERSUS SURGERY ALONE FOR OESOPHAGEAL OR JUNCTIONAL CANCER (CROSS). Ecological Management and Restoration, 2019, 32, .	0.4	0
251	11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy. Journal of Nuclear Medicine, 2020, 62, jnumed.120.251611.	5.0	0
252	Prediction of response to sunitinib in patients with advanced renal cell carcinoma (RCC) using mass spectrometry-based (phospho) proteomics.. Journal of Clinical Oncology, 2021, 39, e16556-e16556.	1.6	0

#	Article	IF	Citations
253	Abstract 4627: Proximal fluid proteome profiling of human colorectal cancer tissue reveals candidate biomarkers for CRC screening. , 2010, , .		0
254	Abstract 5115: Comparative proteomics of exosomes secreted by a panel of cancer cell lines. , 2011, , .		0
255	Abstract 2852: Lysosomal sequestration of sunitinib may play a role in its resistance. , 2011, , .		0
256	Abstract 3533: Acquisition of antigen presenting cell functions by VÎ³9VÎ±2-T cells requires trogocytosis. , 2012, , .		0
257	Abstract 3608: Measurement of kinase activity in cancer cell lines and tumor tissue using a tyrosine kinase peptide substrate array. , 2012, , .		0
258	Abstract 1374: Cross-resistance and sensitivity of sunitinib resistant tumor cells. , 2012, , .		0
259	Response prediction by MALDI-TOF-MS serum peptide profiling of combination treatment with sorafenib and erlotinib in patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2012, 30, e18094-e18094.	1.6	0
260	Abstract 5641: Sunitinib inhibits AXL phosphorylation in tumor cells.. , 2013, , .		0
261	Abstract 4425: Characterisation of cellular transport and accumulation of six clinically approved tyrosine kinase inhibitors (TKIs) in colon cancer cells.. , 2013, , .		0
262	Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3552-3552.	1.6	0
263	Phase I study of dalteparin in combination with sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, e15607-e15607.	1.6	0
264	Mass spectrometry-based serum and plasma peptide profiling for prediction of treatment outcome in patients with cancer.. Journal of Clinical Oncology, 2014, 32, e22221-e22221.	1.6	0
265	Abstract 908: Development of a cell proliferation assay to be used as a read-out system for determining thein vivopotency of bevacizumab in neutralizing the biological activity of VEGF in cancer patients. , 2014, , .		0
266	Abstract A18: Genome-wide methylation profiling to identify potential epigenetic biomarkers associated with response to sunitinib in metastatic renal cell cancer patients (pts). , 2015, , .		0
267	Allowance of tumor-educated platelets for multiclass liquid biopsy-based diagnosis of cancer.. Journal of Clinical Oncology, 2015, 33, 11058-11058.	1.6	0
268	Comparison of deep sequencing miRNA expression analysis in primary colorectal cancer and paired metastases.. Journal of Clinical Oncology, 2015, 33, e14682-e14682.	1.6	0
269	A phase 1 study of weekly high dose sunitinib in patients with advanced solid tumors: Early signs of activity in non-RCC tumor types.. Journal of Clinical Oncology, 2015, 33, e13550-e13550.	1.6	0
270	The ORCHESTRA trial: A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in (mCRC) multi-organ metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, TPS3631-TPS3631.	1.6	0

#	Article	IF	Citations
271	Abstract 1820: Phosphoproteomics of a panel of AML cell lines reveals oncogenic signaling and candidate drivers. , 2015, , .		0
272	Abstract 3991: Standardization and optimization of circulating microRNA serum profiling in patients with cancer. , 2015, , .		0
273	Abstract 2007: Phosphoproteomics scaled-down to tumor biopsies for future TKI treatment selection. , 2015, , .		0
274	Mass spectrometry-based phosphoproteomics of tumor needle biopsies from patients (pts) with advanced solid tumors during treatment with protein kinase inhibitors.. Journal of Clinical Oncology, 2016, 34, 11609-11609.	1.6	0
275	Umbilical cord blood stem cell derived NK cells as universal treatment for metastatic colorectal cancer using EGFR independent killing mechanisms.. Journal of Clinical Oncology, 2016, 34, e14525-e14525.	1.6	0
276	Allogeneic NK cells generated from cord blood as universal treatment for cervical cancer enabled by HLA independent killing mechanisms.. Journal of Clinical Oncology, 2016, 34, e14526-e14526.	1.6	0
277	Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer (AEGC).. Journal of Clinical Oncology, 2016, 34, e15555-e15555.	1.6	0
278	Does treatment-related toxicity affect quality of life in patients with metastatic colorectal cancer? A systematic review.. Journal of Clinical Oncology, 2016, 34, e18106-e18106.	1.6	0
279	Abstract 3885: Peptide-mediated â€˜miniprepâ€™ isolation of extracellular vesicles for high-throughput proteomics; method evaluation and application in colon cancer. , 2016, , .		0
280	Abstract 880: Mapping the metastatic colorectal cancer phospho-proteome for predicting response to cetuximab. , 2016, , .		0
281	Abstract 4928: MiR expression profiles can predict response to systemic treatment in patients with advanced colorectal cancer. , 2016, , .		0
282	Safety and feasibility of adding tumor debulking to palliative chemotherapy in multi-organ metastatic colorectal cancer: The ORCHESTRA trial.. Journal of Clinical Oncology, 2017, 35, 3553-3553.	1.6	0
283	Change in metabolic tumor activity on ¹⁸F-FDG PET after a single dose of cetuximab to predict for treatment benefit, PFS, and OS in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 11519-11519.	1.6	0
284	Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: A phase I exposure escalation study.. Journal of Clinical Oncology, 2017, 35, TPS2620-TPS2620.	1.6	0
285	The Drug Rediscovery Protocol (DRUP).. Journal of Clinical Oncology, 2017, 35, 2547-2547.	1.6	0
286	Abstract 2208: Peptide-mediated 'miniprep' isolation of extracellular vesicles is suitable for high-throughput proteomics; method evaluation and application in colon cancer. , 2017, , .		0
287	Objective smartphone measurements of physical activity and fitness in patients with cancer.. Journal of Clinical Oncology, 2017, 35, 132-132.	1.6	0
288	Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: Results of a phase I exposure escalation study.. Journal of Clinical Oncology, 2018, 36, e14560-e14560.	1.6	0

#	Article	IF	Citations
289	Abstract 2579: Loss of chromosome 18q11.2-18q12.1 is predictive for progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. , 2018, , .		0
290	Comparison of phosphoproteomic profiles in left- and right-sided colorectal cancers.. Journal of Clinical Oncology, 2019, 37, 582-582.	1.6	0
291	Abstract C079: Effect of food on the pharmacokinetics of high dose intermittent sunitinib in patients with advanced solid tumors. , 2019, , .		0
292	634â€…Production and testing of a novel bispecific nanobody construct targeting NK cells and EGFR expressing malignancies. , 2020, , .		0
293	Bulldozing Î²-linked glycolipids for recognition by invariant NKT cells. Immunotherapy, 2012, 4, 20.	2.0	0
294	An Î±-galactosylceramide nose job shapes up iNKT cells. Immunotherapy, 2012, 4, 20-1.	2.0	0
295	ASO Visual Abstract: In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is Not a Prognostic Marker for Survival. Annals of Surgical Oncology, 2022, , 1.	1.5	0